Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of ROS and cAMP-PKA Signaling-related Biomarkers on Renal Disease Severity and Progression in ADPKD

NCT07217158 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07217158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07217158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of ROS and cAMP-PKA Signaling-related Biomarkers on Renal Disease Severity and Progression in ADPKD
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Active, not recruiting
Start date
July 1, 2023
Completion date
June 30, 2027
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease